Propagenix Overview
- Year Founded
-
2014
- Status
-
Acquired/Merged
- Employees
-
5
- Latest Deal Type
-
M&A
Propagenix General Information
Description
Developer of a healthcare technology platform designed to create personalized diagnostics and cell therapies that will enhance human healthcare. The company's systems apply to advanced therapies under development and differentiate primary epithelial adult stem cells for use in generating tissue models for drug discovery and toxicology screening, enabling medical professionals to address the acute shortage of transplantable organs that require mature, functional epithelial tissues such as skin, airways, and kidneys.
Contact Information
Website
www.propagenix.com(Operating Subsidiary)
Corporate Office
- 15810 Gaither Drive
- Suite 230
- Gaithersburg, MD 20877
- United States
Corporate Office
- 15810 Gaither Drive
- Suite 230
- Gaithersburg, MD 20877
- United States
Propagenix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 19-Jan-2024 | 00.00 | Completed | Generating Revenue | ||
| 4. Grant | 15-Jan-2021 | 00000 | 00.00 | Completed | Generating Revenue | |
| 3. Grant | 01-Sep-2018 | 00.000 | 00.00 | Completed | Generating Revenue | |
| 2. Early Stage VC (Series A) | 31-Mar-2016 | $4.2M | $6.5M | 0000 | Completed | Generating Revenue |
| 1. Early Stage VC (Series A) | 22-Apr-2014 | $2.3M | $2.3M | 000.00 | Completed | Startup |
Propagenix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000,000 | 00.000000 | 00.0 | 00.0 | 00 | 00.0 | 000 |
Propagenix Comparisons
Industry
Financing
Details
000000
000000
Propagenix Competitors (5)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Neogene Therapeutics | Formerly VC-backed | Santa Monica, CA | 000 | 00000 | 000000&0 | 00000 |
| NexImmune | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| MatTek | Corporate Backed or Acquired | Ashland, MA | 000 | 000000&0 | ||
| StemCell Technologies | Private Debt Financed | Vancouver, Canada | 0000 | 000.00 | 00000000. 00 | 000.00 |
| HUB Organoids | Accelerator/Incubator Backed | Utrecht, Netherlands | 00 | 000000000000 |
Propagenix Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Propagenix Patents
Propagenix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3841195-A1 | Epithelial cell spheroids | Pending | 20-Aug-2018 | 0000000000 | |
| CA-3107502-A1 | Epithelial cell spheroids | Pending | 20-Aug-2018 | 0000000000 | |
| US-20210189351-A1 | Epithelial cell spheroids | Pending | 20-Aug-2018 | 0000000000 | 0 |
| US-11060715-B2 | Ex vivo proliferation of epithelial cells | Active | 11-Sep-2015 | 0000000000 | 00 |
| US-20200011523-A1 | Ex vivo proliferation of epithelial cells | Active | 11-Sep-2015 | F21V33/0076 |
Propagenix Executive Team (3)
| Name | Title | Board Seat |
|---|---|---|
| Brian Pollok Ph.D | Co-Founder, Chief Executive Officer, President & Advisor | |
| Sharon Challberg Ph.D | Co-Founder & Chief Operating Officer | |
| Richard Schlegel Ph.D | Co-Founder & Chair, Scientific Advisory Council |
Propagenix Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Propagenix Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Maryland Stem Cell Research Fund | Government | 000 0000 | 000000 0 | |
| National Institute of Diabetes and Digestive and Kidney Diseases | Government | 000 0000 | 000000 0 | |
| National Institutes of Health | Government | 000 0000 | 000000 0 | |
| Repleon | Corporation | Minority | 000 0000 | 000000 0 |
| TEDCO | Venture Capital | Minority | 000 0000 | 000000 0 |
Propagenix FAQs
-
When was Propagenix founded?
Propagenix was founded in 2014.
-
Who is the founder of Propagenix?
Brian Pollok Ph.D, Sharon Challberg Ph.D, and Richard Schlegel Ph.D are the founders of Propagenix.
-
Who is the CEO of Propagenix?
Brian Pollok Ph.D is the CEO of Propagenix.
-
Where is Propagenix headquartered?
Propagenix is headquartered in Gaithersburg, MD.
-
What is the size of Propagenix?
Propagenix has 5 total employees.
-
What industry is Propagenix in?
Propagenix’s primary industry is Biotechnology.
-
Is Propagenix a private or public company?
Propagenix is a Private company.
-
What is Propagenix’s current revenue?
The current revenue for Propagenix is 000000.
-
How much funding has Propagenix raised over time?
Propagenix has raised $6.5M.
-
Who are Propagenix’s investors?
Maryland Stem Cell Research Fund, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Repleon, and TEDCO are 5 of 7 investors who have invested in Propagenix.
-
Who are Propagenix’s competitors?
Neogene Therapeutics, NexImmune, MatTek, StemCell Technologies, and HUB Organoids are competitors of Propagenix.
-
When was Propagenix acquired?
Propagenix was acquired on 19-Jan-2024.
-
Who acquired Propagenix?
Propagenix was acquired by StemCell Technologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
